Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESC Congress 2018: MITRA-FR Finds No Benefit Of MitraClip In Severe Secondary MR

Executive Summary

Patients with severe secondary mitral regurgitation treated with MitraClip and medical therapy have the same rate of death or unplanned hospitalization for heart failure at one year as patients treated with medical therapy alone, results of MITRA-FR show. Abbott, as well as other companies developing transcatheter mitral-repair technology, will now look to the COAPT trial to establish MitraClip's benefits on clinical outcomes.

You may also be interested in...



ESC Congress 2018 Wrap-Up: Medtronic's Arctic Front; B. Braun's SeQuent Please; Biotronik's Orsiro Stent

Almost 33,000 cardiology professionals attended the 2018 European Society of Cardiology Congress last week in Munich. The meeting included 4,500 abstracts, including 17 late-breaking clinical trials, six clinical trial updates, and 20 registries. Here are some of the highlights of interest to the medtech industry.

LivaNova Finishes Feasibility Trial Of Transcatheter Mitral Valve, Anticipates 2020 CE Mark

PRELUDE feasibility study of LivaNova's Caisson transseptal transcatheter mitral valve replacement (TMVR) system is complete and the company the INTERLUDE CE Mark trial has begun, the company announced. The company is now working with the US FDA to finalize the protocol for the ENSEMBLE US pivotal trial.

EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise

Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.

Topics

Related Companies

UsernamePublicRestriction

Register

MT123217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel